Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack

Journal of the American College of Cardiology

Volumn 69, Issue 2, 2017, Pages 147-158

  Byun, Young Sup ^a,b   Yang, Xiaohong ^a   Bao, Weihang ^c   DeMicco, David ^c   Laskey, Rachel ^c   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Inje University College of Medicine   (South Korea)

^c PFIZER INC   (United States)

Author keywords

integrated discrimination improvement; net reclassification improvement; oxidation specific epitope; risk factors; statin therapy

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PLACEBO; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; FEMALE; HUMAN; LIPID ANALYSIS; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOSPHOLIPID BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; BLOOD; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SECONDARY PREVENTION; STROKE;

AGED; APOLIPOPROTEIN B-100; ATORVASTATIN CALCIUM; BIOMARKERS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SECONDARY PREVENTION; STROKE;

EID: 85008682026     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.057     Document Type: Article

References (44)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
2. 2 Kim, A.S., Johnston, S.C., Global variation in the relative burden of stroke and ischemic heart disease/clinical perspective. Circulation 124 (2011), 314–323.
3. 3 Leibundgut, G., Scipione, C., Yin, H., et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 54 (2013), 2815–2830.
4. 4 Miller, Y.I., Choi, S.H., Wiesner, P., et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 108 (2011), 235–248.
5. 5 Witztum, J.L., Lichtman, A.H., The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 9 (2014), 73–102.
6. 6 van Dijk, R.A., Kolodgie, F., Ravandi, A., et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 53 (2012), 2773–2790.
7. 7 Ravandi, A., Leibundgut, G., Hung, M.Y., et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol 63 (2014), 1961–1971.
8. 8 Berliner, J.A., Leitinger, N., Tsimikas, S., The role of oxidized phospholipids in atherosclerosis. J Lipid Res 50:Suppl (2009), S207–S212.
9. 9 Kadl, A., Sharma, P.R., Chen, W., et al. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Rad Biol Med 51 (2011), 1903–1909.
10. 10 Tsimikas, S., Miyanohara, A., Hartvigsen, K., et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol 58 (2011), 1715–1727.
11. 11 Schneider, M., Witztum, J.L., Young, S.G., et al. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res 46 (2005), 769–778.
12. 12 Rodenburg, J., Vissers, M.N., Wiegman, A., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 47 (2006), 1803–1810.
13. 13 Fang, L., Harkewicz, R., Hartvigsen, K., et al. Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem 285 (2010), 32343–32351.
14. 14 Tsimikas, S., Willeit, P., Willeit, J., et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 60 (2012), 2218–2229.
15. 15 Tsimikas, S., Duff, G.W., Berger, P.B., et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol 63 (2014), 1724–1734.
16. 16 Byun, Y.S., Lee, J.H., Arsenault, B.J., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65 (2015), 1286–1295.
17. 17 Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
18. 18 van der Valk, F.M., Bekkering, S., Kroon, J., et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134 (2016), 611–624.
19. 19 Willeit, P., Kiechl, S., Kronenberg, F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860.
20. 20 Bergmark, C., Dewan, A., Orsoni, A., et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49 (2008), 2230–2239.
21. 21 Wiesner, P., Tafelmeier, M., Chittka, D., et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res 54 (2013), 1877–1883.
22. 22 Scipione, C.A., Sayegh, S.E., Romagnuolo, R., et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res 56 (2015), 2273–2285.
23. 23 Ridker, P.M., C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49 (2007), 2129–2138.
24. 24 Nambi, V., Hoogeveen, R.C., Chambless, L., et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk In Communities (ARIC) study. Stroke 40 (2009), 376–381.
25. 25 Aviram, M., Rosenblat, M., Bisgaier, C.L., Newton, R.S., Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998), 271–280.
26. 26 Mason, R.P., Walter, M.F., Day, C.A., Jacob, R.F., Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 281 (2006), 9337–9345.
27. 27 Di Sciascio, G., Patti, G., Pasceri, V., Gaspardone, A., Colonna, G., Montinaro, A., Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 54 (2009), 558–565.
28. 28 Kiechl, S., Willeit, J., Mayr, M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007), 1788–1795.
29. 29 Yeang, C., Hung, M.Y., Byun, Y.S., et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol 10 (2016), 594–603.
30. 30 O'Donoghue, M.L., Morrow, D.A., Tsimikas, S., et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 63 (2014), 520–527.
31. 31 Tsimikas, S., The re-emergence of lipoprotein(a) in a broader clinical arena. Prog Cardiovasc Dis 59 (2016), 135–144.
32. 32 Berg, K., Dahlen, G., Christophersen, B., Cook, T., Kjekshus, J., Pedersen, T., Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 52 (1997), 254–261.
33. 33 Khera, A.V., Everett, B.M., Caulfield, M.P., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 129 (2014), 635–642.
34. 34 Albers, J.J., Slee, A., O'Brien, K.D., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 62 (2013), 1575–1579.
35. 35 Nestel, P.J., Barnes, E.H., Tonkin, A.M., et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 33 (2013), 2902–2908.
36. 36 Tsimikas, S., Bergmark, C., Beyer, R.W., et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41 (2003), 360–370.
37. 37 Tsimikas, S., Witztum, J.L., Miller, E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004), 1406–1412.
38. 38 Tsimikas, S., Lau, H.K., Han, K.R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109 (2004), 3164–3170.
39. 39 Fefer, P., Tsimikas, S., Segev, A., et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med 13 (2012), 11–19.
40. 40 Leibundgut, G., Witztum, J.L., Tsimikas, S., Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol 13 (2013), 168–179.
41. 41 Briley-Saebo, K., Yeang, C., Witztum, J.L., Tsimikas, S., Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. J Cardiovasc Transl Res 7 (2014), 719–736.
42. 42 Fang, L., Green, S.R., Baek, J.S., et al. In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest 121 (2011), 4861–4869.
43. 43 Fraley, A.E., Schwartz, G.G., Olsson, A.G., et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 53 (2009), 2186–2196.
44. 44 Langsted, A., Varbo, A., Kamstrup, P.R., Nordestgaard, B.G., Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population. J Clin Endocrinol Metab 100 (2015), 2690–2699.